NASDAQ:ABUS
Arbutus Biopharma Corporation Stock News
$2.60
+0.110 (+4.42%)
At Close: Mar 27, 2024
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
11:27am, Thursday, 04'th May 2023
Here is how Arbutus Biopharma (ABUS) and Hologic (HOLX) have performed compared to their sector so far this year.
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
10:41am, Thursday, 04'th May 2023
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.11 per share a year ago.
Arbutus Biopharma clinical hold slows hepatitis B momentum: broker
02:44pm, Wednesday, 26'th Apr 2023
Analysts at Baird Equity Research have awarded Arbutus Biopharma a ‘Neutral' rating after the early-stage biopharmaceutical company announced that its investigational new drug application for its n
Why Arbutus Biopharma Stock Is Sinking Today
11:50am, Tuesday, 25'th Apr 2023
The FDA has placed a clinical hold on AB-101, Arbutus' experimental chronic hepatitis B virus therapy. Arbutus had hoped to advance AB-101 into early-stage testing and report initial data on it later
Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update
07:30am, Thursday, 20'th Apr 2023
WARMINSTER, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop nove
Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023
04:01pm, Tuesday, 18'th Apr 2023
Two oral presentations scheduled for Thursday, April 27, 2023 WARMINSTER, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical compa
Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update
07:30am, Thursday, 16'th Feb 2023
WARMINSTER, Pa., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel
Arbutus to Participate in Three Upcoming Investor Conferences
07:30am, Monday, 06'th Feb 2023
WARMINSTER, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel
Arbutus Biopharma Corporation (ABUS) Q3 2022 Earnings Call Transcript
10:42am, Wednesday, 09'th Nov 2022
Arbutus Biopharma Corporation (NASDAQ:ABUS ) Q3 2022 Earnings Conference Call January 1, 2022 8:45 AM ET Company Participants Lisa Caperelli - Vice President of Investor Relations Bill Collier - Presi
Arbutus to Present at Jefferies London Healthcare Conference
07:30am, Tuesday, 08'th Nov 2022
WARMINSTER, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel
Arbutus to Present at Chardan's 6th Annual Genetic Medicines Conference
07:30am, Thursday, 22'nd Sep 2022
WARMINSTER, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop nove
Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2022 Results - Earnings Call Transcript
03:06pm, Thursday, 04'th Aug 2022
Arbutus Biopharma Corporation (NASDAQ:ABUS ) Q2 2022 Earnings Conference Call August 4, 2022 8:45 AM ET Company Participants Lisa Caperelli - Vice President of Investor Relations Bill Collier - Presid
Arbutus to Report Second Quarter 2022 Financial Results and Provide Corporate Update
07:30am, Thursday, 21'st Jul 2022
WARMINSTER, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel
Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release
03:36pm, Wednesday, 29'th Jun 2022
Two triple-combination studies using AB-729 for treatment of patients with Hepatitis B are expected in the 2nd half of 2022. A PD-L1 drug is being advanced in the pipeline to eventually add to a tripl
This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B
03:54pm, Tuesday, 28'th Jun 2022
JMP Securities reiterates its Market Outperform rating but reduces the price target to $9 from $10 on Arbutus Biopharma Corp (NASDAQ: ABUS) after data presentation at the European Association for